An Individually Randomized, Placebo-controlled Trial to Measure the Protection Conferred by a Single Dose Regimen of Bivalent, Killed, Whole Cell Oral Cholera Vaccine (Shanchol™) in Dhaka, Bangladesh

Trial Profile

An Individually Randomized, Placebo-controlled Trial to Measure the Protection Conferred by a Single Dose Regimen of Bivalent, Killed, Whole Cell Oral Cholera Vaccine (Shanchol™) in Dhaka, Bangladesh

Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2016

At a glance

  • Drugs Cholera vaccine inactivated (Primary)
  • Indications Cholera
  • Focus Therapeutic Use
  • Acronyms SCVB
  • Most Recent Events

    • 05 May 2016 Results published in the New England Journal of Medicine
    • 05 May 2016 Status changed from recruiting to completed according to results published in the New England Journal of Medicine.
    • 05 May 2016 Primary endpoint has been met (Number of participants with a single dose regimen oral cholera vaccine Shanchol will get protection) according to results published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top